Clinical Trial Update: Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of rivipansel (GMI-1070) in hospitalized sickle cell vaso-occlusive crises was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Vaso-occlusive Crisis

Drugs mentioned

• Rivipansel (rivipansel)

Snippet

Sponsor: GlycoMimetics Incorporated | Conditions: Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Status: TERMINATED